Compare MSGM & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSGM | PHIO |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 14.6M |
| IPO Year | 2020 | 2011 |
| Metric | MSGM | PHIO |
|---|---|---|
| Price | $4.48 | $1.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | 149.6K | ★ 667.1K |
| Earning Date | 06-22-2026 | 06-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 252.13 | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | ★ $741,000.00 | N/A |
| Revenue This Year | $69.07 | N/A |
| Revenue Next Year | $30.56 | N/A |
| P/E Ratio | $3.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $0.81 |
| 52 Week High | $5.78 | $4.19 |
| Indicator | MSGM | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 55.32 |
| Support Level | $2.59 | $1.01 |
| Resistance Level | $4.57 | $1.43 |
| Average True Range (ATR) | 0.53 | 0.08 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 44.12 | 85.58 |
Motorsport Games Inc is a motorsport network company that combines engaging video games with esports competitions and content for racing fans and gamers around the globe. The company has its reportable segments into the development and publishing of interactive racing video games, entertainment content and services, and the organization and facilitation of esports tournaments, competitions, and events for licensed racing games as well as on behalf of third-party video game racing series and other video game publishers. The majority of the revenue is earned from Gaming.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.